The combination of belzutifan plus lenvatinib significantly improved outcomes for patients with clear cell renal cell ...

Anticipated findings from the LITESPARK-011 trial (NCT04586231) to be presented during the 2026 ASCO Genitourinary Cancers ...

The treatment landscape for clear cell renal cell carcinoma (ccRCC) could be due for a shake-up following dual breakthroughs ...

At 24 months overall survival was 62.8% with Welireg plus Lenvima versus 55.4% with Cabometyx. Median overall survival was 34 ...

Antonio Ocejo, MD, discussed a multi-institutional analysis focusing on the clinical outcomes and tolerability of ipilimumab ...

Telix reported FY2025 revenue of $804M, up 56% YoY, with Precision Portfolio products Illuccix and Gozellix contributing $622M. Read why TLX stock is a Buy.

MARCAP investigators conducted the first individual patient data meta-analysis of randomized trials (POSEIDON) evaluating the use and duration hormone therapy with postoperative radiation therapy in ...

A large national study in Denmark following nearly 1,900 patients over almost a decade found that a minimally invasive ...

Combination cut risk of recurrence or death by 28% in patients at high risk of relapse ...

Dosimetry data from the Phase 3 ECLIPSE substudy demonstrated favorable organ radiation absorbed doses supporting administration of 7.4 GBq for ...

A large national study in Denmark following nearly 1,900 patients over almost a decade has found that a minimally invasive ...

The combination of fruquintinib and serplulimab has shown antitumor activity in treatment-naive advanced non-clear cell renal cell carcinoma.